Lilly, Hospira Settle Gemzar Patent Fight

Law360, Los Angeles (August 10, 2011, 4:03 PM EDT) -- Eli Lilly & Co. and Hospira Inc. said Tuesday they had reached a settlement in Hospira’s Illinois suit seeking a declaration that its planned generic version of cancer drug Gemzar did not infringe a Lilly patent.

The parties' stipulation asking U.S. District Judge Milton I. Shandur to dismiss the case ushers in the end of U.S. litigation in an intellectual property fight over the ovarian, breast, lung and pancreatic cancer treatment that has sparked lawsuits between the companies in five countries.

Hospira filed the U.S. complaint...
To view the full article, register now.